Storing Tirzepatide: Best Practices
❄️ Lyophilized Peptide Storage
Store lyophilized teduglutide vials at 2°C to 8°C (36°F–46°F) in the original carton to protect from light. Stable for up to 24 months under recommended conditions. Do not use beyond the expiration date printed on the vial.
💧 Reconstitution
Reconstitute each vial with 0.5 mL of the provided diluent (sterile water for injection). Gently swirl the vial for approximately 15 seconds — do not shake. Allow to stand for up to 2 minutes if undissolved powder remains, then gently swirl again. The reconstituted solution should appear clear and colorless.
⏰ After Reconstitution
Use within 3 hours of reconstitution. Keep at room temperature (20–25°C / 68–77°F) until administration. Do not refrigerate or freeze the reconstituted solution. Discard any unused portion after 3 hours.
❄️ Freezing
Do NOT freeze either the lyophilized vials or the reconstituted solution. If a vial has been frozen, it must be discarded.
🧴 Handling Precautions
Inspect the reconstituted solution visually prior to use. Do not use if the solution appears cloudy, discolored, or contains particulate matter. Each vial is accompanied by a Certificate of Analysis (COA) detailing purity verification via RP-HPLC and Mass Spectrometry (MS). This product is for research use only (RUO).
“Preclinical Research Summary Foundational Studies StudyModelKey FindingsRef Drucker et al.”
References
- Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93(15):7911-7916.
- Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997;15(7):673-677.
- Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275(5):G911-G921.
- Cheeseman CI, Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol. 1996;271(3):G477-G482.
- Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999;96(4):1569-1573.
- Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583.
- Dubé PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131(2):589-605.
- Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48(11):1289-1299.
- Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 1999;277(5):E937-E947.
- Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146(1):22-32.
- Prasad R, Alavi K, Schwartz MZ. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg. 2000;35(2):357-359.
- Yusta B, Holland D, Koehler JA, et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology. 2009;137(3):986-996.
Related Research Questions
Want the complete research review?
View Full Tirzepatide Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.